ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs MXN
18.38771
2.80%
Brent Oil
79.275
-0.76%
Bitcoin
69,064.77
-2.40%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Design Therapeutics Inc (DSGN)

  7. Design Therapeutics Inc (DSGN) Noticias

DSGN

Design Therapeutics (DSGN)

Design Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:DSGN
FechaHoraFuenteTítuloSímboloCompañía
08/05/202415:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DSGNDesign Therapeutics Inc
08/05/202415:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DSGNDesign Therapeutics Inc
08/05/202415:05GlobeNewswire Inc.Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesNASDAQ:DSGNDesign Therapeutics Inc
07/05/202405:30GlobeNewswire Inc.Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
19/03/202415:01GlobeNewswire Inc.Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
19/03/202406:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:DSGNDesign Therapeutics Inc
12/03/202405:30GlobeNewswire Inc.Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateNASDAQ:DSGNDesign Therapeutics Inc
05/01/202415:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
13/11/202315:05GlobeNewswire Inc.Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024NASDAQ:DSGNDesign Therapeutics Inc
06/09/202316:13Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:DSGNDesign Therapeutics Inc
14/08/202315:05GlobeNewswire Inc.Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
14/08/202315:01GlobeNewswire Inc.Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich AtaxiaNASDAQ:DSGNDesign Therapeutics Inc
02/06/202315:32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DSGNDesign Therapeutics Inc
01/06/202315:46Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DSGNDesign Therapeutics Inc
31/05/202305:30GlobeNewswire Inc.Design Therapeutics to Present at the 2023 Jefferies Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
09/05/202315:05GlobeNewswire Inc.Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
24/04/202305:30GlobeNewswire Inc.Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023NASDAQ:DSGNDesign Therapeutics Inc
13/04/202315:41Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:DSGNDesign Therapeutics Inc
03/04/202315:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:DSGNDesign Therapeutics Inc
14/03/202315:27Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:DSGNDesign Therapeutics Inc
14/03/202315:05GlobeNewswire Inc.Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
14/02/202307:16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:DSGNDesign Therapeutics Inc
08/02/202305:30GlobeNewswire Inc.Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma ConferenceNASDAQ:DSGNDesign Therapeutics Inc
22/12/202215:26Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:DSGNDesign Therapeutics Inc
08/12/202207:01TipRanksDesign Therapeutics Tanks Even After Positive Clinical DataNASDAQ:DSGNDesign Therapeutics Inc
07/12/202215:01GlobeNewswire Inc.Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio ProgressNASDAQ:DSGNDesign Therapeutics Inc
03/11/202215:05GlobeNewswire Inc.Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
17/10/202215:05GlobeNewswire Inc.Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022NASDAQ:DSGNDesign Therapeutics Inc
22/09/202205:30GlobeNewswire Inc.Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine SummitNASDAQ:DSGNDesign Therapeutics Inc
16/08/202220:48TipRanksRBC Capital Sticks to Its Buy Rating for Design Therapeutics (DSGN)NASDAQ:DSGNDesign Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DSGN

Su Consulta Reciente

NYSE
DIS
Walt Disney
FX
EURUSD
Euro vs US Dollar
NYSE
JPM
JP Morgan Chase
CCOM
US500
US 500
NYSE
NKE
Nike
COIN
ETHUSD
Ethereum
CCOM
US30
US 30
AMEX
XLV
Health Care Select Sector
NYSE
MCD
McDonalds
AMEX
XLF
Financial Select Sector
FX
EURMXN
Euro vs MXN
SPI
SP500
S&P 500
NYSE
VZ
Verizon Communications
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
MSFT
Microsoft
FX
USDMXN
US Dollar vs MXN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados